{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T06:16:25Z","timestamp":1788156985277,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Capital's Funds for Health Improvement and Research","award":["2026-1-4091"],"award-info":[{"award-number":["2026-1-4091"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82330078"],"award-info":[{"award-number":["82330078"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272554"],"award-info":[{"award-number":["82272554"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"DOI":"10.1007\/s00198-026-08210-3","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T05:48:41Z","timestamp":1788155321000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Body weight predicts denosumab pharmacodynamic duration: a real-world longitudinal cohort study"],"prefix":"10.1007","author":[{"given":"Jinwen","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoze","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Churan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyuan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8234-6924","authenticated-orcid":false,"given":"Chunli","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"issue":"10169","key":"8210_CR1","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/S0140-6736(18)32112-3","volume":"393","author":"JE Compston","year":"2019","unstructured":"Compston JE, McClung MR, Leslie WD (2019) Osteoporosis. Lancet 393(10169):364\u2013376","journal-title":"Lancet"},{"issue":"8","key":"8210_CR2","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756\u2013765","journal-title":"N Engl J Med"},{"issue":"7","key":"8210_CR3","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5(7):513\u2013523","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"8210_CR4","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12325-021-01936-y","volume":"39","author":"DL Kendler","year":"2022","unstructured":"Kendler DL, Cosman F, Stad RK, Ferrari S (2022) Denosumab in the treatment of osteoporosis: 10 years later: a narrative review. Adv Ther 39(1):58\u201374","journal-title":"Adv Ther"},{"issue":"8","key":"8210_CR5","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","volume":"49","author":"RJ Keizer","year":"2010","unstructured":"Keizer RJ, Huitema ADR, Schellens JHM, Beijnen JH (2010) Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49(8):493\u2013507","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"8210_CR6","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2165\/11535960-000000000-00000","volume":"49","author":"NL Dirks","year":"2010","unstructured":"Dirks NL, Meibohm B (2010) Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49(10):633\u2013659","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"8210_CR7","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1177\/0091270009337512","volume":"49","author":"DD Wang","year":"2009","unstructured":"Wang DD, Zhang S, Zhao H, Men AY, Parivar K (2009) Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. J Clin Pharmacol 49(9):1012\u20131024","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"8210_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2005.12.041","volume":"72","author":"DE Mager","year":"2006","unstructured":"Mager DE (2006) Target-mediated drug disposition and dynamics. Biochem Pharmacol 72(1):1\u201310","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"8210_CR9","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1359\/JBMR.040305","volume":"19","author":"PJ Bekker","year":"2004","unstructured":"Bekker PJ, Holloway DL, Rasmussen AS et al (2004) A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19(7):1059\u20131066","journal-title":"J Bone Miner Res"},{"issue":"8","key":"8210_CR10","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1056\/NEJMoa044459","volume":"354","author":"MR McClung","year":"2006","unstructured":"McClung MR, Lewiecki EM, Cohen SB et al (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354(8):821\u2013831","journal-title":"N Engl J Med"},{"issue":"2","key":"8210_CR11","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","volume":"43","author":"PD Miller","year":"2008","unstructured":"Miller PD, Bolognese MA, Lewiecki EM et al (2008) Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 43(2):222\u2013229","journal-title":"Bone"},{"issue":"4","key":"8210_CR12","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1210\/jc.2010-1502","volume":"96","author":"HG Bone","year":"2011","unstructured":"Bone HG, Bolognese MA, Yuen CK et al (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96(4):972\u2013980","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"8210_CR13","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/jbmr.251","volume":"26","author":"R Eastell","year":"2011","unstructured":"Eastell R, Christiansen C, Grauer A et al (2011) Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res 26(3):530\u2013537","journal-title":"J Bone Miner Res"},{"issue":"12","key":"8210_CR14","doi-asserted-by":"publisher","first-page":"793","DOI":"10.2165\/11594240-000000000-00000","volume":"50","author":"L Sutjandra","year":"2011","unstructured":"Sutjandra L, Rodriguez RD, Doshi S et al (2011) Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis. Clin Pharmacokinet 50(12):793\u2013807","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"8210_CR15","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s00198-011-1786-8","volume":"23","author":"T Nakamura","year":"2012","unstructured":"Nakamura T, Matsumoto T, Sugimoto T et al (2012) Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis. Osteoporos Int 23(3):1131\u20131140","journal-title":"Osteoporos Int"},{"issue":"10","key":"8210_CR16","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1210\/jc.2013-3795","volume":"99","author":"JW Mandema","year":"2014","unstructured":"Mandema JW, Zheng J, Libanati C, Perez Ruixo JJ (2014) Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response-based meta-analysis. J Clin Endocrinol Metab 99(10):3746\u20133755","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"8210_CR17","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1158\/1078-0432.CCR-11-2944","volume":"18","author":"S Doshi","year":"2012","unstructured":"Doshi S, Sutjandra L, Zheng J et al (2012) Denosumab dose selection for patients with bone metastases from solid tumors. Clin Cancer Res 18(9):2648\u20132657","journal-title":"Clin Cancer Res"},{"issue":"4","key":"8210_CR18","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2165\/11598090-000000000-00000","volume":"51","author":"L Gibiansky","year":"2012","unstructured":"Gibiansky L, Sutjandra L, Doshi S et al (2012) Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours. Clin Pharmacokinet 51(4):247\u2013260","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"8210_CR19","doi-asserted-by":"publisher","first-page":"516","DOI":"10.7326\/M20-0882","volume":"173","author":"H Lyu","year":"2020","unstructured":"Lyu H, Yoshida K, Zhao SS et al (2020) Delayed denosumab injections and fracture risk among patients with osteoporosis. Ann Intern Med 173(7):516\u2013526","journal-title":"Ann Intern Med"},{"issue":"2","key":"8210_CR20","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","volume":"33","author":"SR Cummings","year":"2018","unstructured":"Cummings SR, Ferrari S, Eastell R et al (2018) Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res 33(2):190\u2013198","journal-title":"J Bone Miner Res"},{"issue":"5","key":"8210_CR21","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1007\/s00198-017-3919-1","volume":"28","author":"MR McClung","year":"2017","unstructured":"McClung MR, Wagman RB, Miller PD et al (2017) Observations following discontinuation of long-term denosumab therapy. Osteoporos Int 28(5):1723\u20131732","journal-title":"Osteoporos Int"},{"issue":"6","key":"8210_CR22","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/jbmr.3110","volume":"32","author":"AD Anastasilakis","year":"2017","unstructured":"Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O (2017) Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res 32(6):1291\u20131296","journal-title":"J Bone Miner Res"},{"issue":"2","key":"8210_CR23","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1210\/jc.2016-3170","volume":"102","author":"O Lamy","year":"2017","unstructured":"Lamy O, Gonzalez-Rodriguez E, Stoll D, Hans D, Aubry-Rozier B (2017) Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report. J Clin Endocrinol Metab 102(2):354\u2013358","journal-title":"J Clin Endocrinol Metab"},{"key":"8210_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","volume":"105","author":"E Tsourdi","year":"2017","unstructured":"Tsourdi E, Langdahl B, Cohen-Solal M et al (2017) Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone 105:11\u201317","journal-title":"Bone"},{"issue":"10","key":"8210_CR25","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1002\/jbmr.149","volume":"25","author":"IR Reid","year":"2010","unstructured":"Reid IR, Miller PD, Brown JP et al (2010) Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res 25(10):2256\u20132265","journal-title":"J Bone Miner Res"},{"issue":"1","key":"8210_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jbmr.1998","volume":"29","author":"E Shane","year":"2014","unstructured":"Shane E, Burr D, Abrahamsen B et al (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29(1):1\u201323","journal-title":"J Bone Miner Res"},{"issue":"18","key":"8210_CR27","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1010650","volume":"364","author":"J Schilcher","year":"2011","unstructured":"Schilcher J, Micha\u00eblsson K, Aspenberg P (2011) Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 364(18):1728\u20131737","journal-title":"N Engl J Med"},{"issue":"4","key":"8210_CR28","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1515\/cclm-2024-1148","volume":"63","author":"G Lombardi","year":"2025","unstructured":"Lombardi G, J\u00f8rgensen NR, Harvey NC et al (2025) Guidelines for the correct use of the nomenclature of biochemical indices of bone status: a position statement of the Joint IOF Working Group and IFCC Committee on Bone Metabolism. Clin Chem Lab Med 63(4):704\u2013711","journal-title":"Clin Chem Lab Med"},{"issue":"1","key":"8210_CR29","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1210\/clinem\/dgaa756","volume":"106","author":"E Tsourdi","year":"2021","unstructured":"Tsourdi E, Zillikens MC, Meier C et al (2021) Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab 106(1):264\u2013281","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"8210_CR30","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","volume":"22","author":"S Vasikaran","year":"2011","unstructured":"Vasikaran S, Eastell R, Bruy\u00e8re O et al (2011) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 22(2):391\u2013420","journal-title":"Osteoporos Int"},{"issue":"12","key":"8210_CR31","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1007\/s00198-025-07703-x","volume":"36","author":"V Jha","year":"2025","unstructured":"Jha V, Bhadada SK, Pal R et al (2025) Personalizing denosumab therapy in postmenopausal Indian women with osteoporosis: predictive role of bone turnover markers and body mass index in determining dosing interval. Osteoporos Int 36(12):2531\u20132539","journal-title":"Osteoporos Int"},{"issue":"5","key":"8210_CR32","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.cell.2021.02.002","volume":"184","author":"MM McDonald","year":"2021","unstructured":"McDonald MM, Khoo WH, Ng PY, Xiao Y, Zamerli J, Thatcher P et al (2021) Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption. Cell 184(5):1330-1347.e13. https:\/\/doi.org\/10.1016\/j.cell.2021.02.002","journal-title":"Cell"},{"issue":"3","key":"8210_CR33","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s12020-022-03230-5","volume":"80","author":"AA Khan","year":"2023","unstructured":"Khan AA, AbuAlrob H, M\u2019Hiri I et al (2023) Effect of low dose denosumab on bone mineral density in postmenopausal women with osteoporosis after a transition from 60 mg dose: a prospective observational study. Endocrine 80(3):647\u2013657","journal-title":"Endocrine"},{"issue":"2","key":"8210_CR34","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1002\/bcp.70275","volume":"92","author":"Y Kuang","year":"2026","unstructured":"Kuang Y, Liu YX, Teng YN et al (2026) Population pharmacokinetic\/pharmacodynamic model of LY06006 in Chinese healthy subjects and postmenopausal osteoporotic women. Br J Clin Pharmacol 92(2):495\u2013503","journal-title":"Br J Clin Pharmacol"},{"key":"8210_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1631034","volume":"16","author":"S Choi","year":"2025","unstructured":"Choi S, Park S, Jung J et al (2025) Population pharmacokinetics\/pharmacodynamics analysis confirming biosimilarity of SB16 to reference denosumab. Front Pharmacol 16:1631034","journal-title":"Front Pharmacol"},{"issue":"1-2","key":"8210_CR36","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1080\/14712598.2024.2308645","volume":"24","author":"B Vogg","year":"2024","unstructured":"Vogg B, Poetzl J, El Galta R, Fuhr R, Schwebig A, Sekhar S (2024) Pharmacokinetics and pharmacodynamics of the proposed biosimilar denosumab GP2411 and reference denosumab in healthy males. Expert Opin Biol Ther 24(1\u20132):91\u2013100. https:\/\/doi.org\/10.1080\/14712598.2024.2308645","journal-title":"Expert Opin Biol Ther"},{"issue":"9","key":"8210_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17091146","volume":"17","author":"S S\u00e1nchez-Vidaurre","year":"2025","unstructured":"S\u00e1nchez-Vidaurre S, Paravisini A, Queiruga-Parada J (2025) Population PK modeling of denosumab biosimilar MB09 and reference denosumab to establish PK similarity. Pharmaceutics 17(9):1146","journal-title":"Pharmaceutics"},{"issue":"10","key":"8210_CR38","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1080\/13543784.2022.2120389","volume":"31","author":"S Wang","year":"2022","unstructured":"Wang S, Yang X, Huang J et al (2022) Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a biosimilar of denosumab (LY06006): a randomized, double-blind, single-dose, parallel-controlled clinical study in healthy Chinese subjects. Expert Opin Investig Drugs 31(10):1133\u20131142","journal-title":"Expert Opin Investig Drugs"},{"issue":"6","key":"8210_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197984","volume":"13","author":"Q Chen","year":"2018","unstructured":"Chen Q, Hu C, Liu Y et al (2018) Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose denosumab in healthy Chinese volunteers: a randomized, single-blind, placebo-controlled study. PLoS ONE 13(6):e0197984","journal-title":"PLoS ONE"},{"key":"8210_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.893166","volume":"13","author":"S Niu","year":"2022","unstructured":"Niu S, Chen M, Yan D et al (2022) A randomized controlled dose-escalation study of LY06006, a recombinant humanized monoclonal antibody to RANKL, in Chinese healthy adults. Front Pharmacol 13:893166","journal-title":"Front Pharmacol"},{"issue":"2","key":"8210_CR41","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/s41401-022-00954-y","volume":"44","author":"H Zhang","year":"2023","unstructured":"Zhang H, Gu JM, Chao AJ et al (2023) A phase III randomized, double-blind, placebo-controlled trial of the denosumab biosimilar QL1206 in postmenopausal Chinese women with osteoporosis and high fracture risk. Acta Pharmacol Sin 44(2):446\u2013453","journal-title":"Acta Pharmacol Sin"},{"key":"8210_CR42","first-page":"117","volume":"38","author":"J Gu","year":"2023","unstructured":"Gu J, Zhang H, Xue Q et al (2023) Denosumab biosimilar (LY06006) in Chinese postmenopausal osteoporotic women: a randomized, double-blind, placebo-controlled, multicenter phase III study. J Orthop Transl 38:117\u2013125","journal-title":"J Orthop Transl"},{"issue":"10","key":"8210_CR43","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1080\/13543784.2023.2273510","volume":"32","author":"HA Lee","year":"2023","unstructured":"Lee HA, Kim S, Seo H, Kim S (2023) A phase I, randomized, double-blind, single-dose pharmacokinetic study to evaluate the biosimilarity of SB16 (proposed denosumab biosimilar) with reference denosumab in healthy male subjects. Expert Opin Investig Drugs 32(10):959\u2013966","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"8210_CR44","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1093\/jbmr\/zjae016","volume":"39","author":"S Jeka","year":"2024","unstructured":"Jeka S, Dokoupilov\u00e1 E, Kivitz A, \u017buchowski P, Vogg B, Krivtsova N et al (2024) Equivalence trial of proposed denosumab biosimilar GP2411 and reference denosumab in postmenopausal osteoporosis: the ROSALIA study. J Bone Miner Res 39(3):202\u2013210. https:\/\/doi.org\/10.1093\/jbmr\/zjae016","journal-title":"J Bone Miner Res"},{"issue":"3","key":"8210_CR45","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1080\/17425255.2024.2432673","volume":"21","author":"R Fuhr","year":"2025","unstructured":"Fuhr R, Sun X, Wang X et al (2025) A three-arm clinical study to compare pharmacokinetic and pharmacodynamic similarity of the denosumab biosimilar LY06006 with reference denosumab in healthy male subjects. Expert Opin Drug Metab Toxicol 21(3):305\u2013313","journal-title":"Expert Opin Drug Metab Toxicol"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08210-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-08210-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08210-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T05:48:42Z","timestamp":1788155322000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-026-08210-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":45,"alternative-id":["8210"],"URL":"https:\/\/doi.org\/10.1007\/s00198-026-08210-3","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"assertion":[{"value":"20 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Peking University Third Hospital Medical Science Research Ethics Committee (M20250019).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Because this was a retrospective study using de-identified electronic medical records, the requirement for informed consent was waived by the ethics committee.","order":2,"name":"Ethics","label":"Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":3,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}